AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06330181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 2
Description: Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study NCT05653856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-PSMA I&T
Description: Radiolabeled Receptor-Targeted Diagnostic Product
Study NCT05632211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT05
Description: Pre filled syringes filled with AVT05
Study NCT05632211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simponi
Description: Pre filled syringes filled with Simponi
Study NCT05556759 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: patient will be operated under general anesthesia
Study NCT05556759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPS
Description: patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
Study NCT05556759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-iliac QL
Description: patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
Study NCT04664790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
Study NCT04664790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Neuropsychologist guided BrainHQ training
Study NCT05043844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal binder
Description: Wearing an abdominal binder postoperatively
Study NCT04695145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in group
Description: Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds
Study NCT04695145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group sessions with leisure activities
Description: The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
Study NCT05044390 — intervention group
Intervention type: PROCEDURE
Intervention: Lung transplantation (single, lobar or bilateral lung transplantation)
Description: Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
Study NCT05968391 — intervention group
Intervention type: RADIATION
Intervention: PET scan metabolic day
Description: 11C-Acetate and 11C-Acetoacetate PET scans
Study NCT04669600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (BIVV020)
Description: Pharmaceutical form:solution for injection
Study NCT05338593 — intervention group
Intervention type: OTHER
Intervention: Outcome
Description: Mortality rate of prolonged therapy.
Study NCT04544189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300mg (oral) once daily, in a 28-day cycle
Study NCT04544189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
Study NCT04544189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
Study NCT04544189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg by mouth once daily, in a 28-day cycle
Study NCT04723303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Lining Stem Cells
Description: An IV infusion of ULSCs will be administered.
Study NCT04814511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InfectoScab 5 % Creme
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
Study NCT04814511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: InfectoScab 5 % Creme
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
Study NCT04814511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin 10 % Creme
Description: Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
Study NCT04814511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Driponin 3 mg Tabletten
Description: Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
Study NCT06512831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
Study NCT05944913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
Study NCT05228756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometer
Description: Participants will complete 16 exercise sessions at home wearing an accelerometer
Study NCT06058884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
Study NCT05337345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified Dose on Specified Days
Study NCT04841213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implantation
Description: Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
Study NCT06268509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutritional panel laboratory examination
Description: As stated in group description
Study NCT06268509 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnancy supplements (other than provided by Ministry of Health)
Description: As stated in group description
Study NCT06268509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fetomaternal ultrasound
Description: As stated in group description
Study NCT05263349 — intervention group
Intervention type: OTHER
Intervention: Typical Dreams Questionnaire
Description: Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003).
Study NCT05263349 — intervention group
Intervention type: OTHER
Intervention: HAD Questionnaire
Description: The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21).
Study NCT05263349 — intervention group
Intervention type: OTHER
Intervention: Dream Booklet
Description: The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
Study NCT04761952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azathioprine
Description: daily orally
Study NCT04761952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: daily orally
Study NCT04761952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: infliximab
Description: intravenously, at 0, 2,6 weeks with every 8-week-interval later
Study NCT05772832 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
Study NCT04761952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: intravenously, at 0, 2,6 weeks with every 8-week-interval later
Study NCT04761952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-3 Polyunsaturated Fatty Acids
Description: Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
Study NCT01674738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 i.v. on day 1 (three-week cycle)
Study NCT01674738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 i.v. on day 1 (three-week cycle)
Study NCT01674738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7,5 mg/kg i.v. on day 1 (three-week cycle)
Study NCT05772832 — intervention group
Intervention type: DRUG
Intervention: Remifentanyl
Description: Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
Study NCT06074068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change
Description: 18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.
Study NCT06074068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Duluth BIP
Description: 18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
Study NCT05746871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilik
Description: The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
Study NCT05746871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Subjects will continue with their standard care for 5 weeks
Study NCT05693558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVD-003, an autologous 3D scaffold free osteogenic graft
Description: Bone correction and grafting surgery
Study NCT05226715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic manual therapy
Description: high velocity low amplitude thrust into a human joint
Study NCT04438304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SARTATE
Description: 64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
Study NCT06434025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Iron Carboxymaltose 500 mg. 2 vials administered IV.
Study NCT06434025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Carboxymaltose
Description: Iron Carboxymaltose 500 mg. 2 vials administered IV.
Study NCT06434025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg Tab, PO, onde a day.
Study NCT06434025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Iron Carboxymaltose
Description: Solution Sodium Chloride 0,9% 100 ml, IV, once.
Study NCT06434025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Dapagliflozin
Description: Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
Study NCT06434025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Dapagliflozin
Description: Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
Study NCT04738604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany
Description: The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
Study NCT04738604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany
Description: The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
Study NCT04738604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)
Description: The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
Study NCT04738604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)
Description: The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
Study NCT04949828 — intervention group
Intervention type: DRUG
Intervention: CREON
Description: Oral Capsules
Study NCT05644015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: escape room game
Description: Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
Study NCT04793685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
Study NCT04793685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation with Relapse Prevention and Contingency Management
Description: 12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
Study NCT04793685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 12-Step Facilitation with Relapse Prevention and Contingency Management
Description: 12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
Study NCT06334120 — intervention group
Intervention type: DRUG
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
Study NCT06206200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive dual task training (intervention group)
Description: Simultaneously performing cognitive tasks and motor rehabilitative exercises.
Study NCT06206200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care physiotherapy (control group)
Description: The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
Study NCT06238011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
Study NCT06238011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
Study NCT05355181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar mobilization techniques
Description: Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges.
Study NCT05355181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scar mobilization techniques
Description: Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges.
Study NCT05355181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Description: Core stabilization exercises
Study NCT04974190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Device
Description: A Nasal Spray apparatus containing a liquid